# Drug of interest
My drug of interest is levofloxacin.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. ABCB1 (z: 3.66)
2. ABCG2 (z: 1.97)
3. HLA-DRB1 (z: 1.83)
4. ABCC2 (z: 1.79)
5. HLA-B (z: 1.78)
6. UGT1A1 (z: 1.61)
7. HLA-DQB1 (z: 1.55)
8. CYP2C19 (z: 1.47)
9. G6PD (z: 1.15)
10. CYP2D6 (z: 1.13)
11. ABCB4 (z: 0.96)
12. CYP2D7 (z: 0.92)
13. ABCC4 (z: 0.85)
14. HLA-DRB3 (z: 0.78)
15. HLA-DPB1 (z: 0.76)
16. HLA-DPA1 (z: 0.75)
17. ABCC1 (z: 0.7)
18. HLA-C (z: 0.67)
19. HLA-DRA (z: 0.66)
20. HLA-DRB5 (z: 0.66)
21. CBR1 (z: 0.65)
22. SLCO1B1 (z: 0.64)
23. CYP2S1 (z: 0.6)
24. CYP1A2 (z: 0.58)
25. NR1I2 (z: 0.57)
26. HLA-DRB4 (z: 0.57)
27. HLA-E (z: 0.57)
28. HLA-G (z: 0.57)
29. HLA-DQA1 (z: 0.54)
30. UGT1A9 (z: 0.53)
31. CBR3 (z: 0.53)
32. CYP1A1 (z: 0.48)
33. SLC22A1 (z: 0.46)
34. CYP3A4 (z: 0.45)
35. UGT1A8 (z: 0.43)
36. HLA-A (z: 0.43)
37. SLC22A3 (z: 0.43)
38. ABCC5 (z: 0.42)
39. CYP2C9 (z: 0.41)
40. SLC22A2 (z: 0.39)
41. UGT1A3 (z: 0.38)
42. UGT1A4 (z: 0.35)
43. ABCC11 (z: 0.34)
44. RUNDC3B (z: 0.34)
45. NAT2 (z: 0.33)
46. CYP3A5 (z: 0.32)
47. SLC22A16 (z: 0.31)
48. HLA-DOB (z: 0.31)
49. ABCB6 (z: 0.3)
50. UGT1A6 (z: 0.29)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**levofloxacin**: Genetic variations in the CYP2C9 enzyme can minimally impact the metabolism of the fluoroquinolone antibiotic levofloxacin, while variants in ABCB1, coding for P-glycoprotein, can affect the drug’s cellular efflux, impacting its concentration in target tissues, thus influencing efficacy and safety. Furthermore, genes such as SLC22A1, SLC22A2, SLC22A4, SLCO1A2, and SLCO4C1, which are involved in renal secretion and organic anion transport, may also influence levofloxacin's excretion and overall pharmacokinetics.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**HLA-DRB1**: The HLA-DRB1 gene, through its various alleles, significantly influences the pharmacogenetic interactions that affect the efficacy and safety of medications, causing immune-mediated hypersensitivity reactions. For instance, the HLA-DRB1*15:01 allele is linked to abacavir hypersensitivity in HIV treatment, while HLA-DRB1*07:01 is associated with hepatic injuries from ximelagatran, highlighting the importance of understanding a patient's HLA-DRB1 allele status to optimize and personalize treatment strategies.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**UGT1A1**: UGT1A1 plays a critical role in drug metabolism primarily through glucuronidation, affecting both pharmacokinetics and pharmacodynamics. For example, the gene’s variations, like UGT1A1*28, reduce the clearance of drugs such as irinotecan's active metabolite SN-38, leading to severe side effects and requiring dosage adjustments. Similarly, UGT1A1 influences the metabolism of HIV drugs like atazanavir and indinavir, impacting their effectiveness and concentration in the body. This gene also affects the metabolism of other medications such as atorvastatin, impacting treatments across various therapeutic areas like cancer and lipid management.

**HLA-DQB1**: HLA-DQB1 gene variants significantly impact drug hypersensitivity reactions, particularly for drugs like abacavir, allopurinol, nevirapine, lamotrigine, and carbamazepine, which can cause severe reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis in genetically predisposed individuals. These interactions emphasize the role of HLA-DQB1 in pharmacodynamics, affecting drug safety and efficacy rather than drug metabolism.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**HLA-DRB3**: HLA-DRB3, a gene involved in immune system response, interacts with drugs not by being directly targeted but by influencing how the immune system interacts with these drugs, thus modulating their effects and potentially leading to drug hypersensitivity reactions. For example, variations in HLA-DRB3 are linked to different responses and adverse reactions to drugs like clozapine, where a connection is suggested between HLA alleles and clozapine-induced agranulocytosis, highlighting the gene's role in drug efficacy and safety.

**HLA-DPB1**: HLA-DPB1, a gene expressed in antigen-presenting cells, primarily affects drug hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) through immune modulation, particularly in pharmacodynamic interactions. For example, its specific alleles may increase the risk of agranulocytosis in patients treated with the antipsychotic drug clozapine, while there is no confirmed pharmacogenetic interaction between HLA-DPB1 and aspirin.

**HLA-DPA1**: HLA-DPA1 influences immune responses and plays a significant role in hypersensitivity to drugs such as abacavir, used in HIV treatment, due to its function in antigen presentation and subsequent immune activation. While it doesn’t affect the metabolism or elimination of aspirin, it may impact the immune-mediated adverse reactions to aspirin, suggesting a potential pharmacodynamic interaction through modulation of inflammatory pathways.

**ABCC1**: ABCC1, a critical gene encoding for an efflux transporter, significantly affects the pharmacokinetics and pharmacodynamics of various drugs by impacting their absorption, distribution, and elimination. Notably, it modulates the clearance of anticancer drugs like SN-38 and doxorubicin from cells, contributing to drug resistance and variability in therapeutic efficacy and toxicity, which is particularly relevant in optimizing cancer chemotherapy. Other drugs such as vincristine, methotrexate, and ritonavir, among others, also demonstrate pharmacogenetic interactions with ABCC1, affecting treatment outcomes especially in oncology.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**HLA-DRA**: The HLA-DRA gene, though not directly interacting with drugs through pharmacokinetic pathways, plays an indirect role in pharmacodynamics due to its involvement in the immune system. It is implicated in the immune-mediated drug reactions, such as hypersensitivities to antibiotics like amoxicillin, flucloxacillin, and clavulanate, possibly by affecting how drug-related antigens are presented to the immune system by antigen-presenting cells, thereby influencing the likelihood or severity of allergic reactions.

**HLA-DRB5**: HLA-DRB5 affects the pharmacogenetics of clavulanate, amoxicillin, and clozapine by modulating immune responses rather than altering drug metabolism or transport. In the cases of clavulanate and amoxicillin, this can lead to hypersensitivity reactions, while for clozapine, it can influence the risk of agranulocytosis, all due to variations in HLA-DRB5 that affect the immune system's reaction to these drugs.

**CBR1**: CBR1 notably affects the metabolism of chemotherapeutic drugs such as doxorubicin and daunorubicin by reducing them into less active compounds like doxorubicinol, thereby potentially altering their effectiveness and toxicity, particularly influencing cardiotoxicity risks. Genetic variants in CBR1 can lead to varied metabolism rates, impacting drug plasma levels and toxicity, while its interactions with other drugs like fluorouracil and cyclophosphamide, though less definitively understood, suggest modifications in drug efficacy and safety through carbonyl reduction.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**CYP1A2**: CYP1A2 plays a pivotal role in the pharmacokinetics of drugs, influencing their metabolism and, consequently, efficacy and safety. This enzyme is responsible for processing medications such as clozapine, theophylline, caffeine, erlotinib, deferasirox, escitalopram, and clopidogrel, where genetic variability can significantly affect therapeutic outcomes and requires careful dosage adjustments to prevent toxicity or enhance drug effectiveness.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**HLA-DRB4**: HLA-DRB4 gene primarily affects the immune system and influences the treatment response to disease-modifying antirheumatic drugs (DMARDs) in conditions like rheumatoid arthritis by affecting how specific alleles impact disease progression and drug responsiveness. While HLA-DRB4 does not directly interact with drugs, its role may affect the efficacy and adverse effects of treatments such as DMARDs and indirectly influence immune responses related to drugs like clozapine, though robust data on direct interactions is lacking.

**HLA-E**: The gene HLA-E, which plays a significant role in immune system regulation, may interact pharmacodynamically with methotrexate, a drug used for autoimmune diseases and cancer. This interaction likely occurs as methotrexate modulates immune responses that are under the control of HLA-E, affecting drug efficacy and potential adverse effects rather than affecting the drug's absorption, distribution, metabolism, or excretion.

**HLA-G**: HLA-G's potential pharmacodynamic interactions with drugs like fluorouracil, irinotecan, methotrexate, and capecitabine, primarily used in chemotherapy, relate to its role in modulating immune responses which could influence the immune system's ability to recognize and destroy tumor cells. These interactions likely result from HLA-G enhancing immune evasion capabilities in cancer cells, thereby potentially modifying the therapeutic efficacy of the mentioned drugs.

**HLA-DQA1**: Specific HLA-DQA1 alleles are linked to drug-induced hypersensitivity reactions with medications such as abacavir, flucloxacillin, lumiracoxib, and others. These alleles influence the immune system's response to these drugs, leading to heightened or adverse reactions, emphasizing the role of HLA-DQA1 in modulating the immune response to certain medications.

**UGT1A9**: UGT1A9 plays a key role in the glucuronidation and metabolism of various drugs, including NSAIDs like diclofenac, antiretrovirals, and chemotherapy agents like irinotecan. Genetic variations in UGT1A9 can significantly influence the pharmacokinetics and pharmacodynamics of these drugs, affecting their efficacy and the severity of side effects such as neutropenia, particularly evident in treatments involving mycophenolic acid and irinotecan.

**CBR3**: CBR3, an enzyme involved in metabolizing drugs by reducing carbonyl groups to alcohols, significantly influences the pharmacokinetics of the chemotherapy drug doxorubicin, altering its efficacy and toxicity due to genetic variations such as CBR3 V244M. This variation affects how different individuals process doxorubicin, potentially necessitating customized dosage adjustments. Furthermore, CBR3 might interact similarly with other chemotherapy agents like docetaxel and paclitaxel, impacting their plasma concentrations and therapeutic effects.

**CYP1A1**: CYP1A1, an important enzyme in drug metabolism, exhibits pharmacogenetic interactions that impact the efficacy and toxicity of drugs like theophylline and clozapine through variations in metabolic activity based on genetic differences. Drugs such as deferasirox, valproic acid, and caffeine among others show altered pharmacokinetics when metabolized by CYP1A1, while others like imatinib and nilotinib might have altered pharmacodynamics or metabolism influenced by CYP1A1 activity, affecting treatment outcomes especially in cancer therapy.

**SLC22A1**: The gene SLC22A1, encoding for the organic cation transporter 1 (OCT1), significantly influences the absorption and distribution of various drugs, such as metformin, tramadol, lamotrigine, ondansetron, rasagiline, and imatinib, by affecting their hepatic uptake. Genetic variations in SLC22A1 can lead to different efficacy and safety profiles for these drugs, necessitating potential dosage adjustments in the management of conditions like diabetes, pain, epilepsy, nausea, Parkinson’s disease, and chronic myeloid leukemia.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**UGT1A8**: UGT1A8 plays a crucial role in the metabolism of drugs such as atorvastatin, axitinib, valproic acid, methotrexate, and raloxifene by catalyzing their glucuronidation, leading to the formation of water-soluble glucuronide conjugates that facilitate drug excretion. Variants in the UGT1A8 gene can modify the activity of the enzyme, thereby affecting the concentration, efficacy, and toxicity of these drugs, with notable effects on drugs like irinotecan, where altered metabolism significantly impacts its toxicity profile.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**SLC22A3**: The gene SLC22A3, or OCT3, influences the pharmacokinetics of drugs like metformin and potentially antidepressants like citalopram by affecting their cellular uptake and distribution. Variants in SLC22A3 can lead to altered drug efficiency and side effect profiles by impacting the transporter efficiency and thus the intracellular concentrations of these medications.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**SLC22A2**: SLC22A2, functioning as the organic cation transporter 2 (OCT2), plays a key role in the renal elimination of various drugs, including metformin, acyclovir, ganciclovir, oxaliplatin, cimetidine, and l-tryptophan, with genetic variations affecting their pharmacokinetics. Reduced activity of SLC22A2 can limit the elimination of drugs like metformin, potentially increasing its efficacy but also raising the risk of toxicity, while other drugs might experience altered efficacy and safety due to changes in exposure levels caused by interactions and competition at the transporter level.

**UGT1A3**: Variations in the UGT1A3 gene, critical for the glucuronidation process, influence the metabolism and clinical effects of drugs such as atorvastatin, deferasirox, telmisartan, valproic acid, methotrexate, and montelukast. These interactions can alter drug clearance, efficacy, side effects, and toxicity, highlighting the importance of considering genetic factors in drug dosing and therapy optimization.

**UGT1A4**: UGT1A4 catalyzes the glucuronidation of drugs such as lamotrigine, atorvastatin, valproic acid, methotrexate, testosterone, tamoxifen, anastrozole, olanzapine, and n-desmethylclozapine, affecting their solubility, detoxification, and excretion. Genetic variations in UGT1A4 can significantly alter the metabolism of these drugs, including lamotrigine and hormonal treatments like testosterone and tamoxifen, impacting their therapeutic effectiveness and risk of toxicity, which is crucial for managing conditions ranging from epilepsy and cholesterol to hormone-sensitive disorders and psychiatric conditions.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**RUNDC3B**: Although the gene RUNDC3B is primarily involved in intracellular trafficking, its potential pharmacogenetic interaction with imatinib, a tyrosine kinase inhibitor used in cancer treatment, remains speculative. Given RUNDC3B's role in cellular dynamics, there is a possibility that it could influence the intracellular concentration and efficacy of imatinib in cancer cells, particularly those with varying expressions of RUNDC3B; however, this interaction lacks concrete evidence and is still under exploration.

**NAT2**: The NAT2 gene encodes an enzyme crucial for the metabolism of various drugs through N-acetylation, influencing their pharmacokinetics and toxicity. Variants in NAT2 affect the metabolism of drugs like isoniazid, hydralazine, procainamide, sulfamethoxazole, and pyrazinamide, leading to differences in acetylator status (rapid, intermediate, slow) among individuals, which impacts drug plasma levels, exposure duration, and risk of adverse effects such as increased toxicity and drug-induced lupus.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**SLC22A16**: SLC22A16 plays a critical role in the pharmacokinetics of doxorubicin, a chemotherapeutic drug, by affecting its transport and thereby influencing the drug's efficacy and potential for cardiac toxicity. Although primarily involved with doxorubicin, SLC22A16 may also affect other chemotherapy drugs like fluorouracil and cyclophosphamide, potentially altering their metabolism or mechanisms of action rather than their transport.

**HLA-DOB**: The gene HLA-DOB, which regulates antigen presentation, may affect the efficacy and safety of immune-modulating drugs used in conditions like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis by altering T cell activity. While the exact pharmacogenetic interactions are not well-defined, it is plausible that different HLA-DOB variants could lead to varied treatment outcomes in diseases requiring modulation of the immune system.

**ABCB6**: ABCB6 mutations impact the pharmacokinetics of drugs like cyclophosphamide and doxorubicin by affecting their absorption into cells and intracellular storage, which influences the drugs’ effectiveness and toxicity. This variation in drug handling due to ABCB6 can significantly alter the therapeutic efficacy and side effects of these chemotherapeutic agents, underscoring the importance of genetic considerations in cancer treatment planning.

**UGT1A6**: UGT1A6 is a key enzyme involved in the metabolism of several drugs through glucuronidation, influencing their solubility and excretion. Specific genetic variants of UGT1A6 can alter the metabolism and effectiveness of drugs like atorvastatin and acetaminophen, potentially affecting their efficacy and toxicity. Additionally, it processes drugs such as valproic acid, methotrexate, aspirin, and other NSAIDs, where genetic differences can impact drug levels, exposure, and side effect profiles, playing a significant role in pharmacokinetics and potentially pharmacodynamics.
